Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 179.60B |
| Revenue (ttm) | 54.17B |
| Net Income (ttm) | 13.97B |
| Shares Out | n/a |
| EPS (ttm) | 5.52 |
| PE Ratio | 12.86 |
| Forward PE | 9.36 |
| Dividend | 2.91 (4.05%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 3,685 |
| Average Volume | 4,162 |
| Open | 71.50 |
| Previous Close | 72.60 |
| Day's Range | 71.00 - 72.00 |
| 52-Week Range | 65.50 - 102.00 |
| Beta | 0.37 |
| RSI | 45.81 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck (MRK) Achieves Key Survival Milestone in Ovarian Cancer Trial
Merck (MRK) Achieves Key Survival Milestone in Ovarian Cancer Trial
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck hits secondary goal in late-stage trial for Keytruda in ovarian cancer
Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room
Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming Q3 earnings release.
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...
Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets
The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.
Germany's Merck tweaks mid-term healthcare unit guidance
German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.
Merck: A Golden Buying Opportunity
See Which Of The Latest 13F Filers Holds MRK
At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 09/30/2025 reporting period, and noticed that Merck & Co Inc (Symbol: MRK) was held by 13 of these fund...
Merck (MRK) Reports Positive Outcomes for New HIV-1 Treatment
Merck (MRK) Reports Positive Outcomes for New HIV-1 Treatment
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE: MRK) on Wednesday announced ad...
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced addi...
Merck reports positive data from HIV-1 treatment study
Merck (MRK) Presents Positive Data from HIV-1 Treatment Trials
Merck (MRK) Presents Positive Data from HIV-1 Treatment Trials
Merck to Acquire the Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the signing of a definitive agreement to acquire the chromatography business of JSR Life Sciences,...
Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of th...
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ: NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine . • NVAX stock is showing exc...
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
The pharmaceutical giant has seen brighter days.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck: An Undervalued Stock In An Expensive Market
Merck (MRK) Receives Neutral Rating from Citi with Price Target Boost
Merck (MRK) Receives Neutral Rating from Citi with Price Target Boost
Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.
Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...
High Margins, Lower Price: Is This Merck Stock's Buying Window?
Merck (MRK) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
Behind the Scenes of Merck & Co's Latest Options Trends
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE: MRK). And retail traders should know. We noticed this today when the positions showed up on publicly available ...
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conf...